Idoxifene对人乳内动脉的舒张作用

为了研究idoxifene(吲哚昔酚,一种新型雌激素受体调节剂)对人乳内动脉(human internal mammarya artery,HIMA)的舒张作用及其机制,采用离体血管灌流的方法,观察idoxifene对完整内皮和去内皮HIMA的舒张作用,以及L-NAME和美蓝(metllylene blue,MB)对这一过程的影响,并且和17β雌二醇(17β-estradiol,E2)的舒血管作用进行了比较。实验中观察到保留血管内皮时idoxifenc(0．01～10μmol／L)和E2(0．1～100μmol／I,)可以剂量依赖性地舒张血管,且血管对idoxifene的灵敏度比对E2高15倍左右,而去内皮时则无此作用;NO合成酶阻断剂L-NAME和鸟苷酸环化酶(guanylate cyclasc,GC)的抑制剂MB使idoxifene舒张HIMA的作用完全消失。上述结果表明：idoxifene能够剂量依赖性地舒张HIMA,而且比E2更有效。idoxifene的这种作用是通过NO-GC-cGMP通路实现的。

Vasorelaxing effect of idoxifene on human internal mammary arteries

The purpose of this study was to investigate the vasorelaxing effect and mechanism of idoxifene (a new estrogen receptor modulator) on human internal mammary artery (HIMA). HIMA segments were harvested from men during coronary artery bypass grafting surgery. Patients with diabetes mellitus, hypercholesterolemia, hypertension, or smoking habit were excluded. The vasorelaxing effect of idoxifene on artery rings from HIMA with and without endothelium was measured by means of perfusion in vitro. Cumulative dose-response to idoxifene in the range of 0.01-10 micromol/L was observed in the presence and absence of NO synthase inhibitor L-NAME. It was also studied whether the vasodilation effect of idoxifene on HIMA was blocked by methylene blue (MB), an inhibitor of guanylate cyclase (GC). The results obtained from idoxifene were compared with those from 17beta-estradiol (E(2)). It was found that idoxifene caused a concentration-dependent relaxation on HIMA. The dose range was from 0.03 micromol/L (minimal vasodilatory concentration) to 3 mmol/L (maximal vasodilatory concentration). It was also found that the vasorelaxation effect of idoxifene on HIMA was dependent on endothelium. E(2) (0.1-100 micromol/L) also resulted in an endothelium-dependent vasorelaxation, but the vessels were 15-fold less sensitive to E(2) than to idoxifene in their vasorelaxation responses. The EC(50) for E(2) was 4.65+/-0.34 micromol/L, compared with 0.32+/-0.02 micromol/L for idoxifene. The mean maximal vasodilatory value of E(2) was 88.3+/-5.7%, compared with 88.6+/-7.2% for idoxifene. Pretreatment with L-NAME (100micromol/L) abolished idoxifene-induced vasodilation virtually by blocking nitric oxide production. The vasorelaxing effect of idoxifene disappeared in the presence of MB (10 micromol/L). These findings demonstrate that idoxifene results in an endothelium-dependent vasorelaxation of HIMA, like estrogen. The effect of idoxifene is more potent than that of traditional estrogen, and is possibly mediated by NO-GC-cGMP pathway.